Peptide Match

The tool cross-references your stated research goals, experience level, and profile data against a curated database of 65+ compounds. Each compound is assigned an evidence grade (A through C) based on the volume and quality of published clinical and preclinical research available on PubMed, FDA regulatory status, and mechanism-of-action data. Results are ranked by evidence quality and goal alignment.

Grade A indicates FDA-approved compounds or those with extensive Phase III clinical trial data and established safety profiles. Grade B indicates compounds with substantial preclinical evidence and/or Phase I-II clinical data supporting their mechanism of action. Grade C indicates emerging research compounds with primarily in-vitro or early animal model data. Each grade reflects the current state of published evidence, not a claim of efficacy.

BPC-157 is a 15-amino-acid gastric pentadecapeptide that supports tissue repair through angiogenesis and growth factor modulation (VEGF, FGF). TB-500 (Thymosin Beta-4 fragment) promotes cell migration and differentiation with broader systemic anti-inflammatory effects. BPC-157 is typically studied for localized tissue and gut repair, while TB-500 shows wider systemic activity. They are frequently combined in research protocols for synergistic repair mechanisms.

GLP-1 agonists (Semaglutide, Tirzepatide) mimic incretin hormones, slowing gastric emptying, reducing hypothalamic appetite signaling, and improving insulin sensitivity. Clinical trials demonstrate 15-25% body weight reduction. Newer triple agonists like Retatrutide add glucagon receptor activity for enhanced energy expenditure. Non-GLP-1 alternatives such as AOD-9604 target fat metabolism through different pathways without affecting blood glucose.

FDA-approved peptide therapeutics in the database include Semaglutide (Ozempic/Wegovy), Tirzepatide (Mounjaro/Zepbound), Tesamorelin (Egrifta), PT-141/Bremelanotide (Vyleesi), and Pentosan Polysulfate (Elmiron). These are marked with an "FDA Approved" tag in results. Many additional compounds are in various stages of clinical trials and regulatory review.

Key factors include GMP certification status, availability of batch-specific Certificates of Analysis (COA), third-party analytical testing (HPLC purity verification, mass spectrometry identity confirmation), heavy metal and endotoxin screening, US-based manufacturing, and community verification history. Our vendor table above reflects independent assessment across these criteria.

No. This is an educational research resource that aggregates published scientific literature. It does not provide medical advice, diagnosis, or treatment recommendations. All compound information reflects published research data and should be evaluated in consultation with qualified healthcare professionals.

The database is reviewed monthly against new PubMed publications, FDA regulatory actions, and clinical trial registry updates (ClinicalTrials.gov). Evidence grades are re-evaluated quarterly based on cumulative published data. Last database update noted in the page header stats.